Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$947M |
| 2 |
Tesla
TSLA
|
+$608M |
| 3 |
Microsoft
MSFT
|
+$444M |
| 4 |
Accenture
ACN
|
+$409M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.06B |
| 2 |
Texas Instruments
TXN
|
+$1.92B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.81B |
| 4 |
Starbucks
SBUX
|
+$1.42B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$1,000M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.52% |
| 2 | Financials | 7.13% |
| 3 | Consumer Discretionary | 6.46% |
| 4 | Healthcare | 5.43% |
| 5 | Communication Services | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3801
ADC Therapeutics
ADCT
$134M
| $402K | ﹤0.01% |
127,739
+93,890
| +277% | +$296K |
|
3802
Avita Medical
RCEL
$135M
| $402K | ﹤0.01% |
37,503
+28,979
| +340% | +$272K |
|
|
INZY
3803
DELISTED
Inozyme Pharma
INZY
| $401K | ﹤0.01% |
76,730
+55,497
| +261% | +$288K |
|
3804
Biomea Fusion
BMEA
$84.6M
| $400K | ﹤0.01% |
39,620
+24,162
| +156% | +$157K |
|
3805
Zevra Therapeutics
ZVRA
$562M
| $400K | ﹤0.01% |
57,599
+42,926
| +293% | +$291K |
|
3806
West Bancorporation
WTBA
$478M
| $399K | ﹤0.01% |
20,977
+15,615
| +291% | +$299K |
|
3807
Global Water Resources
GWRS
$206M
| $399K | ﹤0.01% |
31,663
+14,936
| +89% | +$186K |
|
3808
Ranger Energy Services
RNGR
$376M
| $398K | ﹤0.01% |
33,404
+15,139
| +83% | +$175K |
|
3809
Fidelity D&D Bancorp
FDBC
$306M
| $398K | ﹤0.01% |
8,061
+5,082
| +171% | +$251K |
|
3810
CALL
Stryker
SYK
$125B
| $397K | ﹤0.01% |
1,100
-15,600
| -93% | -$5.38M |
|
3811
Chunghwa Telecom
CHT
$33.1B
| $397K | ﹤0.01% |
+10,000
| New | +$380K |
|
|
BHR
3812
Braemar Hotels & Resorts
BHR
$156M
| $394K | ﹤0.01% |
127,641
+45,284
| +55% | +$142K |
|
3813
The Honest Company
HNST
$402M
| $394K | ﹤0.01% |
110,386
+82,713
| +299% | +$310K |
|
3814
Larimar Therapeutics
LRMR
$397M
| $393K | ﹤0.01% |
60,032
+45,781
| +321% | +$368K |
|
|
THRD
3815
DELISTED
Third Harmonic Bio
THRD
| $393K | ﹤0.01% |
29,012
+18,710
| +182% | +$232K |
|
3816
Freedom Holding
FRHC
$9.63B
| $393K | ﹤0.01% |
4,144
+3,840
| +1,263% | +$334K |
|
3817
Viemed Healthcare
VMD
$447M
| $392K | ﹤0.01% |
53,439
+41,358
| +342% | +$295K |
|
3818
Security National Financial
SNFCA
$244M
| $391K | ﹤0.01% |
46,841
+8,544
| +22% | +$64K |
|
|
LENZ
3819
LENZ Therapeutics
LENZ
$166M
| $391K | ﹤0.01% |
16,463
+12,051
| +273% | +$267K |
|
3820
Velocity Financial
VEL
$689M
| $391K | ﹤0.01% |
19,916
+11,583
| +139% | +$219K |
|
|
NOA
3821
North American Construction
NOA
$369M
| $390K | ﹤0.01% |
20,867
+6,774
| +48% | +$128K |
|
3822
Frontier Group Holdings
ULCC
$1.55B
| $390K | ﹤0.01% |
72,866
+57,642
| +379% | +$225K |
|
3823
American Vanguard Corp
AVD
$68.4M
| $387K | ﹤0.01% |
73,112
+27,229
| +59% | +$193K |
|
3824
NI Holdings
NODK
$310M
| $387K | ﹤0.01% |
24,687
+7,549
| +44% | +$115K |
|
3825
Rubrik
RBRK
$14.9B
| $387K | ﹤0.01% |
12,029
+7,029
| +141% | +$233K |
|
Similar funds
Barclays's Q3 2024 Portfolio in Review
As of Q3 2024, Barclays held 5,593 positions worth $377B, up 15% from $327B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $31.3B of net new capital in Q3 2024, opening 785 new positions and adding to 2,954 existing holdings. Its largest new stake was Smurfit Westrock: 3,460,710 shares worth $171M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $2.06B trimmed.
- Barclays's largest Q3 2024 buy was Smurfit Westrock: 3,460,710 shares worth $171M.
- Barclays added most to iShares US Real Estate ETF in Q3 2024, an estimated $947M increase.
- Barclays's biggest Q3 2024 reduction was CRH, cutting an estimated $2.06B.
- Barclays fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $51.3M.
- Barclays's ten largest holdings make up 41% of its $377B portfolio in Q3 2024.
- Barclays opened 785 new positions and closed 322 in Q3 2024.
- Barclays's portfolio value rose 15% quarter-over-quarter to $377B.
Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.